Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Siller Matula, Jolanta M ^a   Lang, Irene M ^a   Neunteufl, Thomas ^a   Kozinski, Marek ^b   Maurer, Gerald ^a   Linkowska, Katarzyna ^b   Grzybowski, Tomasz ^b   Kubica, Jacek ^b   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19;

ABCB1 GENE; ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CYP2C19 17 GENE; CYP2C19 2 GENE; DIABETES MELLITUS; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HEART MUSCLE ISCHEMIA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PON1 GENE; PROSPECTIVE STUDY; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; AGED; CORONARY ARTERY DISEASE; GENETICS; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

AGED; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 84904625695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102701     Document Type: Article

References (49)

1. Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, et al. (2013) Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality. JACC Cardiovasc Interv 6: 1111-1128.
2. Geisler T, Zurn C, Simonenko R, Rapin M, Kraibooj H, et al. (2010) Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 31: 59-66.
3. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, et al. (2012) Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. Jama 308: 1785-1794.
4. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, et al. (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49: 2312-2317. (Pubitemid 46891710)
5. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, et al. (2008) Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52: 734-739.
6. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, et al. (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45: 1392-1396. (Pubitemid 40615608)
7. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, et al. (2006) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4: 542-549.
8. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, et al. (2010) Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay. J Thromb Haemost 8: 351-359.
9. Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, et al. (2013) Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 167: 2018-2023.
10. Angiolillo DJ (2009) Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 32: 531-540.
11. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, et al. (2008) The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6: 54-61.
12. Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, et al. (2011) Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. Jama 306: 1765-1774.
13. Neubauer H, Kaiser AF, Endres HG, Kruger JC, Engelhardt A, et al. (2011) Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 9: 3.
14. Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, et al. (2011) CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 4: 422-428.
15. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, et al. (2009) Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drugeluting coronary stent thrombosis. Am J Cardiol 103: 806-811.
16. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309-317.
17. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
18. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama 302: 849-857.
19. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, et al. (2011) Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 32: 459-466.
20. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, et al. (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17: 110-116.
21. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, et al. (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 32: 1605-1613.
22. Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, et al. (2011) Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 4: 429-436.
23. Simon T, Steg PG, Becquemont L, Verstuyft C, Kotti S, et al. (2011) Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 90: 561-567.
24. Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, et al. (2012) Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 10: 529-542.
25. Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, et al. (2011) Diurnal variation in platelet inhibition by clopidogrel. Platelets 22: 579-587.
26. Kasprzak M, Kozinski M, Bielis L, Boinska J, Plazuk W, et al. (2009) Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 16: 535-544.
27. Siller-Matula JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, et al. (2012) Continuous thrombin infusion leads to a bleeding phenotype in sheep. Thromb Res 130: 226-236.
28. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, et al. (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115: 2344-2351. (Pubitemid 46685903)
29. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, et al. (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306: 1215-1223.
30. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, et al. (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57: 2474-2483.
31. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, et al. (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121: 512-518.
32. Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, et al. (2011) Effect of CYP2C19*2 and*3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 4: 585-594.
33. Campo G, Ferraresi P, Marchesini J, Bernardi F, Valgimigli M (2011) Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Thromb Haemost 9: 2106-2108.
34. Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, et al. (2013) Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 167: 430-435.
35. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, et al. (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376: 1320-1328.
36. Bhatt DL, Pare G, Eikelboom JW, Simonsen KL, Emison ES, et al. (2012) The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J.
37. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, et al. (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet.
38. So DYF, Wells G, McPherson R, Labinaz M, Glover C, et al. (2013) A Pharmacogenomic approach to antiplatelet therapy in STEMI patients: reassessment of anti-platelet therapy using an individualized strategy in patents with ST-elevation myocardial infarction (The RAPID STEMI study). J Am Coll Cardiol 61: doi:10.1016/S0735-1097(1013)60006-60006.
39. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015. (Pubitemid 350106708)
40. Siller-Matula JM (2012) Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice? Jama 307: 2318-2320.
41. Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, et al. (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55: 2427-2434.
42. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, et al. (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9: 1251-1259.
43. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, et al. (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50: 1541-1547.
44. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, et al. (2007) A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28: 1814-1819.
45. Kozinski M, Obonska K, Stankowska K, Navarese EP, Fabiszak T, et al. (2014) Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J doi: 10.5603/CJ.a2014.0026.: in press.
46. Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, et al. (2011) Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 9: 1730-1737.
47. Mega JL, Hochholzer W, Frelinger AL, 3rd, Kluk MJ, Angiolillo DJ, et al. (2011) Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. Jama 306: 2221-2228.
48. Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, et al. (2011) High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 4: 392-402.
49. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, et al. (2012) Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Interv 5: 797-804.